載入...
Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is currently approved in Japan for treatment of breast cancer. However, apart from phase I clinical trials, data regarding Japanese patients are scant. In the present study, the efficacy and safety of nab-paclitaxel therapy were retrospectively...
Na minha lista:
| 發表在: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
D.A. Spandidos
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4356397/ https://ncbi.nlm.nih.gov/pubmed/25789050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.2954 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|